Hypertension is a common and serious problem and contributes in a major way to global cardiovascular morbidity and mortality. The degree and duration of elevation in either systolic or diastolic blood pressure substantially increases the risk of developing a cardiovascular event or renal disease. [1] [2] [3] Persons with a family history of hypertension or those who are obese are at particularly high risk of developing hypertension. Hypertension-induced vascular or target organ injury can be prevented or delayed by reducing arterial pressure to Ͻ140/90 mm Hg. 4 Results of any clinical trial that examines the effects of blood pressure control on renal disease progression must be considered in the context of the type and magnitude of intervention, eg blood pressure goal in the trial, angiotensin-converting enzyme (ACE) inhibitors vs other agents, as well as the stage of the renal disease at trial inception. Renal function declines at different rates based on the aetiology of the renal disease, eg diabetes vs membranous nephropathy vs IgA nephropathy. 5 Moreover, the timing of achieving blood pressure goal is critically important in order to prevent the 'avalanche effect' of renal disease progression. Specifically, intervention to a blood pressure goal of Ͻ130/85 mm Hg in the very early stages of renal dysfunction, ie glomerular filtration rates (GFR) of Ͼ85Ͻ100 ml/min, is very likely to stop disease progression, whereas intervention when GFR is Ͻ60 ml/min, will only slow its progression. The difference in timing of intervention is similar to an avalanche coming down a mountain: the farther down the mountain, the less likely it can be stopped.
This concept is exemplified by the results of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial, where the average levels of GFR were Ͼ80 ml/min at the start of the trial vs other diabetes trials where the GFR is generally Ͻ60 ml/min at baseline. 6 GFR decline was virtually stopped with early blood pressure intervention in the ABCD trial, whereas in other trials of more advanced renal disease GFR loss occurred at a rate of 2-7 ml/min/year. 7 Furthermore, blood pressure levels in the intensively treated group of the ABCD trial averaged Ͻ130/80 mm Hg. Thus, results of clinical trials in patients with advanced renal disease should not be extrapolated to patients with very early disease, since rates of decline in renal function are not uniformly linear. It is clear, however, that the earlier goal blood pressure is achieved the more likely renal function will be preserved and nephropathy progression halted.
In this issue of Journal of Human Hypertension, Dr Hsu presents a meta-analysis of 10 randomised controlled trials in patients with generally normal renal function. None of these trials had, as a primary outcome, a renal endpoint that would include, doubling of serum creatinine or time to dialysis. 8 The author concludes that blood pressure reduction in these trials reduced cardiovascular events but had little to no impact on renal disease development. This is not a surprise, since in all trials with a primary renal endpoint cardiovascular events occur earlier than renal endpoints. Thus, none of the trials reviewed in this meta-analysis had the power to detect any renal events.
Renal dysfunction, both structural and functional, is often demonstrable in hypertensive patients, even those with minimally elevated arterial pressure over long periods of time. The remarkable pathological changes are hyalinisation and sclerosis of the walls of the afferent arterioles, the hallmark of hypertensive nephrosclerosis. Involvement of the kidney is usually asymptomatic, with the first objective sign being microalbuminuria, a marker of impaired endo-Journal of Human Hypertension thelial responsiveness. [9] [10] [11] In spite of this, only a small minority of patients with essential hypertension develop progressive renal insufficiency, but the incidence of renal insufficiency does rise progressively with every 10 mm Hg increment in systolic pressure. 2, 12 African-American patients and those with diabetes have a higher likelihood of developing progressive renal disease than the general population. [12] [13] Often end-stage renal disease (ESRD) in African-Americans is attributed to hypertensive nephrosclerosis. This might be due to poor hypertension control related to limited access to health care or some other factors. 12 However, retrospective analyses of clinical trials indicate that renal function may continue to decline in African-Americans even when hypertension is as well controlled as in whites. 12 This data has prompted the multi-centred, double-blind placebo controlled trial, the African-American Study of Kidney Disease (AASK), to evaluate the effects of both level of blood pressure control and type of antihypertensive agents used to achieve such levels on progression of renal disease.
14 This study includes over a thousand African-Americans who have documents hypertensive renal disease. 15 Thus, hypertensive renal disease does exist and its rate of progression may be substantially slowed by aggressive reduction of blood pressure. Hence, evaluation of target organ damage and aggressive lowering of blood pressure are particularly important in AfricanAmericans in order to protect against cardiovascular events and slow the progression of renal disease.
Clinical trials in patients in whom renal disease is already present, eg those with GFRs of р60 mls/min, uniformly demonstrate a marked slowing in renal disease progression at lower levels of blood pressure, Figure 1 . The first trial to randomise to two different levels of blood pressure in people with established renal disease (GFRs Ͻ60 mls/min), the Figure 1 Relationship between the levels of achieved blood pressure in prospective trials of patients with renal insufficiency and rates of decline in renal function. Adapted from Bakris et al. 16 Modification of Dietary Protein in Renal Disease (MDRD) trial, clearly demonstrated that those with 1 gram or more of proteinuria and/or AfricanAmericans had slower rates of decline in GFR at blood pressure levels of Ͻ125/75 mm Hg as compared to Ͻ140/90 mm Hg. 13 In this and other trials that achieved a separation of at least 5 mm Hg in diastolic blood pressure levels, the rates of decline in renal function were slower, Figure 1 . 16 Additionally, the number of antihypertensive medications needed to achieve these lower goals averaged 3.2 different medications, Figure 2 . 17 Trials with primary renal endpoints in people with established renal disease such as the Ramipril Efficacy in Nephropathy (REIN), Angiotensin Converting Enzyme Inhibitor and Progressive Renal Insufficiency (AIPRI) and Modification of Dietary Protein in Renal Disease (MDRD) trials, as well as other smaller trials, establish the ability of antihypertensive therapy to slow the progression of nondiabetic renal disease. 13, 16, 18, 19 Two separate studies and a meta-analysis in patients with non-diabetic renal disease further emphasise the point that the level of blood pressure reduction rather than the antihypertensive agent used determines renal protection. [20] [21] [22] A doubleblind, prospective trial in patients with non-diabetic renal disease followed for an average of 3. years demonstrated no difference in the slope of GFR decline between ACE inhibitor and beta-blocker treatment despite comparable blood pressure control. 22 Moreover, retrospective analyses of data from clinical trials indicated that if the blood pressure goal of Ͻ130/85 mm Hg is achieved, decline in renal function is maximally slowed regardless of the agents used, Figure 1 . 16, 23 These trials, taken together with other long-term studies that have evaluated progression of renal disease in the context of blood pressure reduction, clearly provide guidance in the management of Figure 2 Number of antihypertensive medications required to achieve blood pressure goals in all clinical trials that randomised to two different levels of blood pressure. Note that three of these trials are in non-diabetic patients with either very early or no renal dysfunction present. Adapted from Sheinfeld and Bakris.
hypertensive patients with renal dysfunction. They demonstrate that in hypertensive patients with renal insufficiency, a systolic blood pressure Ͻ130 mm Hg and diastolic blood pressure Ͻ80-85 mm Hg will offer better renal protection than higher levels of pressure. Secondly, they show that the goal blood pressure in patients with renal insufficiency of any cause and urinary protein excretion above 1 gram/day should be Ͻ125/75 mm Hg. Third, they reveal that the number of different antihypertensive agents needed to achieve the recommended goal blood pressure of Ͻ130/85 mm Hg is an average 3.2 ( Figure 2) . Finally, they show that regardless of antihypertensive agent used, if this goal blood pressure is achieved renal disease progression will be markedly slowed and cardiovascular risk reduced.
The goal blood pressure for patients with renal disease and/or diabetes as outlined by JNC VI is р130/85 mm Hg. More recently, both the National Kidney Foundation and the Canadian Hypertension Society stated that blood pressure should be reduced to Ͻ130/80 mm Hg in those with renal disease and/or diabetes. 4, 16, 24 Recent data from the renal outcomes in the Hypertension Optimal Treatment (HOT) trial also demonstrate that participants who achieved a mean arterial pressure of less than 94 mm Hg were significantly less likely to have an increase of more than 0.2 mg/dl in serum creatinine at trial end when compared to those with mean arterial pressures above this value. 25 Since cardiovascular death or related morbid events most commonly occur in patients with diabetes and those with renal disease, coupled with the fact that the average life span is about 5 years, once a person starts dialysis, should herald a call for achievement of the JNC VI and recent National Kidney Foundation blood pressure goals of Ͻ130/80 mm Hg. In this way there is a strong likelihood of reducing cardiovascular events and markedly reducing the risk of renal disease progression. Moreover, in the United Kingdom Prospective Diabetes (UKPDS) trial, aggressive blood pressure reduction had a relatively greater impact on cardiovascular risk reduction as compared to aggressive glucose control. 26 Even Dr Hsu states 'this meta-analysis should not be used to argue against treating patients with non-malignant hypertension, since there are clear non-renal benefits'. Physicians should, therefore, be attentive to specific blood pressure goals and not be satisfied until they are achieved. In this way both cardiovascular morbidity and mortality can be markedly reduced and renal disease may not even develop.
